Recently, Shanghai AikeBai Biopharma Technology Co., Ltd. announced that its drug AikeBike™ (generic name: ziresovir/ziresovir) has obtained positive results in a multicenter Phase III clinical trial, reaching the primary endpoint and key secondary endpoint. In this clinical trial named AirFLO, Aisvir™ significantly reduced symptom scores (p=0.002) and viral load (p=0.006) in RSV-infected infants compared with placebo. This study is the world's first phase III clinical trial of oral RSV antiviral drugs to obtain positive results.
Director of Beijing Children's Hospital Affiliated to Capital Medical University, Director of , National Children's Medical Center, and the main investigator of the AirFLO trial, said: "According to the WHO report, about 64 million children worldwide are infected with respiratory syncytial virus every year, of which 160,000 children die from respiratory syncytial disease due to respiratory syncytial disease The related diseases caused by toxic infection of are an important cause of death in children. We urgently need a safe, effective and convenient treatment drug. The positive results of the AirFLO study suggest that the situation of anti-RSV infection drug treatment may change, which is of great significance to the development of pediatric clinical diagnosis and treatment of RSV infection. If ziresovir can be successfully launched, it will be expected to break through the dilemma of no drugs available for the disease and fill a big gap in the antiviral field at home and abroad. "What virus is
respiratory syncytial virus?
Respiratory syncytial virus (RSV), also known as human respiratory syncytial virus (hRSV), is a very common negative sense single-strand RNA virus. Since cells infected with RSV fuse together to form a large cell structure called syncytial, respiratory syncytial virus is therefore named.
According to the 2017 Lancet paper, in 2015, 33.1 million acute lower respiratory tract infection of in children induced by respiratory syncytial virus in in 2015, resulting in about 3.2 million hospitalized children and 59,600 (48,000-74,500) deaths in hospitals in children under 5 years of age. Among children under 6 months of age, 1.4 million hospitalized cases and 27,300 hospitalized deaths are caused by RSV-ALRI, which may have a total mortality rate of up to 118,200.
In addition, research reports said that during the epidemic of seasonal respiratory infection in North America, respiratory syncytial virus accounts for 50% to 80% of all hospitalized cases of bronchitis and 800,000 children under 1 year old suffer from RSV bronchitis, which is the main reason for hospitalization in the United States. Children under 5 years old are 57,527 hospitalized for RSV each year, the highest proportion is 1 year old.
RSV infection is one of the main reasons for infancy and young children in the world. It is extremely contagious and recurring. Even if infants and young children are cured, they are very likely to be infected again in their future lives. RSV is mainly transmitted through droplets, which makes it prone to cause explosive infections in community and hospital settings, posing a great threat to public health and social stability. How to detect respiratory syncytial virus in
?
respiratory syncytial virus (RSV) is one of the most important pathogens for lower respiratory tract infection of in infants and young children worldwide. In recent years, studies have found that it can cause lower respiratory tract infections in adults, middle-aged and elderly people and immunosuppressed patients. Not only that, the mortality rate of RSV infection in adults is as high as 4%. There is currently no vaccine that can be controlled, so early detection, early prevention and early treatment are crucial.
summary
respiratory syncytial virus is negative-strand RNA virus . It is a common pathogen of respiratory infection . It is prevalent all year round and can be combined with covid-19. It is the main cause of inducing lower respiratory tract infection in young children worldwide and leading to hospitalization and death. The gold standard for clinical detection of respiratory syncytial virus is PCR detection of . At present, antiviral drugs, vaccines and monoclonal antibodies of respiratory syncytial virus are in the clinical development stage and there is no special treatment yet. Early detection, early diagnosis and early treatment are crucial.
